| COVID-19 Clinical Research Studies | Lifetime | 75 | GR 2 | 99.48 |
| Sepsis Diagnosis and Treatment | Lifetime | 65 | GR 1 | 99.63 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 84 | GR 2 | 99.43 |
| Long-Term Effects of COVID-19 | Lifetime | 98 | GR 1 | 98.83 |
| Inflammation biomarkers and pathways | Lifetime | 11 | GR 1 | 98.75 |
| Nosocomial Infections in ICU | Lifetime | 51 | GR 1 | 99.38 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 11 | GR 1 | 98.52 |
| Immune Response and Inflammation | Lifetime | 330 | GR 2 | 99.13 |
| Colorectal and Anal Carcinomas | Lifetime | 171 | GR 1 | 98.65 |
| Antibiotic Resistance in Bacteria | Lifetime | 334 | GR 5 | 98.89 |
| Pneumonia and Respiratory Infections | Lifetime | 347 | GR 2 | 98.77 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 348 | GR 1 | 98.14 |
| Immune responses and vaccinations | Lifetime | 100 | GR 1 | 96.23 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 583 | GR 3 | 97.15 |
| Inflammasome and immune disorders | Lifetime | 534 | GR 4 | 95.41 |
| Neonatal and Maternal Infections | Lifetime | 298 | GR 2 | 95.56 |
| Adrenal Hormones and Disorders | Lifetime | 940 | GR 17 | 92.13 |
| Chemotherapy-related skin toxicity | Lifetime | 739 | GR 11 | 82.61 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 10 | GR 1 | 99.73 |
| COVID-19 Clinical Research Studies | 2021-2025 | 75 | GR 2 | 99.52 |
| Long-Term Effects of COVID-19 | 2021-2025 | 111 | GR 1 | 98.61 |
| Colorectal and Anal Carcinomas | 2021-2025 | 27 | GR 1 | 98.38 |
| Immune Response and Inflammation | 2021-2025 | 35 | GR 1 | 96.72 |
| Nosocomial Infections in ICU | 2021-2025 | 54 | GR 1 | 95.79 |
| Pneumonia and Respiratory Infections | 2021-2025 | 185 | GR 1 | 95.74 |
| Inflammation biomarkers and pathways | 2021-2025 | 10 | GR 1 | 93.63 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 25 | GR 1 | 96.88 |
| Immune responses and vaccinations | 2021-2025 | 63 | GR 1 | 91.66 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 535 | GR 2 | 92.14 |
| Streptococcal Infections and Treatments | 2021-2025 | 305 | GR 2 | 87.31 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 420 | GR 4 | 88.46 |
| Adrenal Hormones and Disorders | 2021-2025 | 190 | GR 4 | 88.34 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 690 | GR 12 | 84.96 |
| Microscopic Colitis | 2021-2025 | 987 | GR 7 | 85.74 |
| Neonatal and Maternal Infections | 2021-2025 | 273 | GR 11 | 79.78 |
| Chemotherapy-related skin toxicity | 2021-2025 | 125 | GR 3 | 76.87 |
| Dermatological and COVID-19 studies | 2021-2025 | 469 | GR 9 | 61.48 |
| Thermal Regulation in Medicine | 2021-2025 | 822 | GR 14 | 58.06 |
